What is baicalin and what plant does it come from?

Baicalin is a flavonoid glycoside (flavone-7-O-glucuronide) and the principal bioactive compound extracted from the dried roots of Scutellaria baicalensis Georgi, commonly known as Chinese skullcap or Huang Qin in Traditional Chinese Medicine. It is also found in smaller quantities in Oroxylum indicum. Upon intestinal absorption, baicalin is hydrolyzed to its more lipophilic aglycone, baicalein, which is considered the primary pharmacologically active form at the cellular level.

What does baicalin do in the body?

Baicalin exerts its main effects by inhibiting the NF-κB inflammatory signaling pathway and suppressing the NLRP3 inflammasome, thereby reducing production of pro-inflammatory cytokines including TNF-α, IL-6, IL-1β, and IL-17. It simultaneously activates the PI3K/Akt/NRF2/HO-1 antioxidant pathway, scavenging reactive oxygen species and protecting mitochondrial function. These dual anti-inflammatory and antioxidant mechanisms underlie its preclinically demonstrated benefits in models of neurodegeneration, gastrointestinal inflammation, pulmonary fibrosis, and cardiovascular disease.

Is there clinical trial evidence that baicalin works in humans?

As of current published literature, robust human clinical trial evidence specifically for isolated baicalin is limited; most published studies are in vitro cell experiments or in vivo rodent models using doses of 30–150 mg/kg. Scutellaria baicalensis root appears in human TCM combination formula studies, but isolating baicalin's individual contribution is methodologically challenging. Until adequately powered Phase II/III randomized controlled trials with defined endpoints and effect sizes are completed, clinical efficacy in humans cannot be confirmed, and the evidence is classified as preliminary.

What is the recommended dose of baicalin supplements?

No standardized human dose for isolated baicalin has been established because large-scale clinical trials have not been conducted. Commercial supplements typically provide 200–500 mg of standardized Scutellaria baicalensis extract (often 85–95% baicalin by HPLC) per serving. Animal study doses of 30–150 mg/kg do not directly translate to human equivalents, and baicalin's low and variable oral bioavailability further complicates dose determination; individuals should follow product labeling and consult a healthcare provider.

Are there any side effects or drug interactions with baicalin?

Baicalin has not produced significant toxicity in preclinical models, but comprehensive human safety data are absent. Of particular concern, baicalin and its metabolite baicalein inhibit cytochrome P450 enzymes including CYP1A2, CYP2C9, and CYP3A4 in vitro, which could theoretically increase or decrease plasma levels of medications such as warfarin, statins, and certain antivirals. Use during pregnancy and lactation is not recommended due to a lack of safety data, and those on anticoagulants, immunosuppressants, or hepatotoxic drugs should seek medical guidance before supplementing.

How does baicalin work differently than other herbal anti-inflammatory compounds?

Baicalin has a dual mechanism of action that targets both the NF-κB signaling pathway and the NLRP3 inflammasome, which are central regulators of inflammatory cascades in the body. This dual targeting is more comprehensive than single-pathway inhibitors, allowing baicalin to suppress multiple pro-inflammatory cytokines (IL-6, IL-1β, TNF-α, and IL-17) simultaneously. Most other herbal anti-inflammatory compounds like curcumin or resveratrol primarily work through NF-κB alone, making baicalin's mechanism distinctly broader in scope.

Can baicalin help protect the brain from age-related cognitive decline?

Baicalin activates the PI3K/Akt/NRF2 pathway, which is a key neuroprotective mechanism that defends brain cells against oxidative stress and neuroinflammation—two primary drivers of cognitive decline. By reducing neuroinflammatory cytokine release, baicalin helps maintain a healthier brain microenvironment that supports neuronal function and plasticity. While preclinical evidence is promising, human clinical trials specifically measuring cognitive outcomes in aging populations are still limited.

Is baicalin from Scutellaria baicalensis better absorbed than baicalin in other forms?

Baicalin from Scutellaria baicalensis root extract is a plant-derived form that must undergo deglycosylation in the gut to be converted to its more bioavailable metabolite, baicalein, which crosses the blood-brain barrier more efficiently. Standardized extracts of Scutellaria baicalensis (typically 30–40% baicalin) provide consistent bioavailability compared to isolated baicalin alone, though individual absorption varies based on gut microbiota composition. Co-administration with certain foods or prebiotics may enhance the conversion of baicalin to baicalein, potentially improving overall bioavailability.

Baicalin

Baicalin is a flavonoid glycoside that exerts anti-inflammatory and antioxidant effects primarily by inhibiting NF-κB signaling, suppressing the NLRP3 inflammasome, and activating the PI3K/Akt/NRF2/HO-1 antioxidant axis. Preclinical animal models demonstrate dose-dependent reductions in pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and tissue injury markers at doses of 30–150 mg/kg, though no standardized human clinical trial data currently establishes efficacious doses in people.

Category: Compound Evidence: 1/10 Tier: Preliminary

Origin & History

Baicalin is a flavonoid glycoside predominantly extracted from the dried roots of Scutellaria baicalensis Georgi, a perennial herb native to northeastern China, Mongolia, Russia, and Korea, where it thrives in grasslands and rocky slopes at elevations up to 2,000 meters. A secondary botanical source is Oroxylum indicum, a tree distributed across South and Southeast Asia. The roots of Scutellaria baicalensis, known in Chinese as Huang Qin, have been cultivated and harvested in Chinese herbal medicine for over 2,000 years, with root drying and aqueous or ethanolic extraction remaining the primary preparation methods for isolating baicalin.

Historical & Cultural Context

Scutellaria baicalensis root, designated Huang Qin in Traditional Chinese Medicine, has been documented in Chinese pharmacopeias for over 2,000 years, with its earliest classical reference appearing in the Shennong Bencao Jing (Divine Farmer's Materia Medica, compiled circa 200 CE), where it was classified as a bitter cold herb used to clear heat, dry dampness, and detoxify. Historically, Huang Qin was prescribed for febrile illness, dysentery, jaundice, hemorrhage, and fetal restlessness, reflecting its broad anti-inflammatory and antimicrobial applications recognized empirically before the isolation of baicalin as its principal bioactive constituent. In Korean traditional medicine (Hanbang) and Japanese Kampo, Scutellaria root similarly features in classical compound formulas such as Huang Qin Tang (Ogi-to in Japanese), widely used for gastrointestinal inflammatory conditions. The isolation and structural characterization of baicalin as a flavone-7-O-glucuronide was achieved in the 20th century, linking the root's traditional applications to specific molecular mechanisms now under active pharmacological investigation.

Health Benefits

- **Anti-inflammatory Activity**: Baicalin suppresses NF-κB pathway activation and inhibits the NLRP3 inflammasome, reducing circulating levels of IL-6, IL-1β, TNF-α, and IL-17 in multiple preclinical inflammatory models including ulcerative colitis and pulmonary arterial hypertension.
- **Neuroprotection**: By activating the PI3K/Akt/NRF2 pathway and reducing neuroinflammatory cytokine release, baicalin has demonstrated protective effects against oxidative neuronal damage in rodent models of neurodegeneration, with mitochondrial membrane potential restoration as a key mechanism.
- **Antioxidant Defense**: Baicalin and its aglycone baicalein directly scavenge reactive oxygen species (ROS) and upregulate endogenous antioxidant enzymes including heme oxygenase-1 (HO-1) and Keap1/NRF2-regulated proteins, reducing oxidative tissue burden.
- **Hepatoprotection**: Preclinical data indicate that baicalin attenuates hepatic fibrosis by downregulating TGF-β1 and suppressing ERK1/2-mediated collagen deposition; in mouse models, 120 mg/kg/day IP for 28 days significantly reduced hydroxyproline content and collagen accumulation in lung and liver tissue.
- **Antiviral and Antimicrobial Properties**: Baicalin has demonstrated inhibitory activity against multiple viruses and bacteria in vitro, including influenza and SARS-associated coronaviruses, attributed to direct interference with viral entry mechanisms and immune modulation.
- **Anticancer Potential**: Through modulation of Bcl-2/Bax ratio, caspase-3/9 activation, and ERK/p38 MAPK signaling, baicalin promotes apoptosis in several cancer cell lines in vitro while sparing normal cells, though these findings remain confined to preclinical settings.
- **Cardiopulmonary Protection**: In hypoxic rat models of pulmonary arterial hypertension, baicalin at 30 mg/kg significantly inhibited p38 MAPK and MMP-9 expression, reducing vascular remodeling and right ventricular hypertrophy.

How It Works

Baicalin's primary anti-inflammatory mechanism involves inhibition of the NF-κB signaling cascade, preventing nuclear translocation of p65 and thereby suppressing transcription of pro-inflammatory cytokines including TNF-α, IL-6, IL-1β, and IL-17. Concurrently, baicalin blocks NLRP3 inflammasome assembly and activation, reducing caspase-1-mediated maturation of IL-1β and IL-18. On the cytoprotective side, baicalin activates the PI3K/Akt pathway, which stabilizes NRF2 by inhibiting Keap1-mediated degradation, leading to transcriptional upregulation of HO-1 and other phase II antioxidant enzymes that neutralize ROS and mitigate oxidative stress. Its aglycone metabolite baicalein, generated via intestinal hydrolysis, contributes additional activity through modulation of Bcl-2 family proteins, mitochondrial membrane potential stabilization, and inhibition of pERK1/2 and p38 MAPK-driven fibrotic and apoptotic signaling.

Scientific Research

The body of evidence for baicalin consists predominantly of in vitro cell culture studies and in vivo rodent experiments, with very limited published human clinical trial data available as of 2024. Animal studies have used doses of 30–150 mg/kg administered orally or intraperitoneally across models of ulcerative colitis, pulmonary arterial hypertension, pulmonary fibrosis, and neuroinflammation, consistently reporting statistically significant reductions in inflammatory biomarkers and histopathological damage scores. Review literature acknowledges that translation to human pharmacokinetics is uncertain due to baicalin's poor aqueous solubility and variable oral bioavailability, and no large randomized controlled trials with clearly defined primary endpoints, sample sizes, and effect sizes have been published in major databases. The overall evidence base supports biological plausibility but remains classified as preliminary pending adequately powered human trials.

Clinical Summary

No Phase III or large-scale Phase II randomized controlled trials for baicalin as an isolated compound have been published with full outcomes data as of current literature review. Smaller exploratory human studies exist for Scutellaria baicalensis root extract preparations in traditional Chinese medicine combination formulas, but isolating baicalin's individual contribution is methodologically difficult in these contexts. Preclinical effect sizes are consistently strong across rodent inflammatory models, with MPO, NO, TNF-α, and IL-6 reductions of 30–70% observed at doses of 50–150 mg/kg, yet interspecies dose extrapolation and bioavailability differences make direct human dose equivalence unreliable. Confidence in clinical utility for humans remains low-to-moderate, and regulatory agencies have not approved baicalin as a therapeutic agent for any indication.

Nutritional Profile

Baicalin is a pure phytochemical compound (flavone-7-O-glucuronide) rather than a whole food, and therefore does not contribute macronutrients, essential vitamins, or minerals in supplemental doses. As a flavonoid glycoside, its molecular weight is 446.36 g/mol; hydrolysis in the intestinal tract by beta-glucuronidase yields the aglycone baicalein (270.24 g/mol) and glucuronic acid. Scutellaria baicalensis root dry weight contains baicalin as one of its most abundant flavonoids, alongside baicalein, wogonoside, wogonin, and oroxylin A, with baicalin concentrations in high-quality dried root material reported in the range of 10–15% by dry weight in some analytical studies. Bioavailability is limited by baicalin's low aqueous solubility (log P approximately 1.04) and susceptibility to first-pass hepatic metabolism; peak plasma concentrations following oral dosing in rodents are reached within 30–60 minutes but are substantially lower than administered dose due to incomplete absorption.

Preparation & Dosage

- **Dried Root Extract (Standardized)**: Most commercial supplements are standardized to 85–95% baicalin by HPLC; typical capsule doses range from 200–500 mg extract per serving, though no clinically validated human dose exists.
- **Traditional Decoction (Huang Qin Tang)**: Dried Scutellaria baicalensis roots are simmered in water for 30–60 minutes; this preparation has been used in TCM for centuries but delivers variable baicalin concentrations.
- **Animal Study Reference Doses**: Efficacious doses in rodent models range from 30 mg/kg (cardiovascular/anti-inflammatory) to 150 mg/kg (gastrointestinal inflammation), which do not translate directly to human equivalents without allometric scaling and bioavailability adjustment.
- **Bioavailability Enhancement Formulations**: Emerging research explores nanoparticle encapsulation, phospholipid complexes, and co-administration with absorption enhancers to address baicalin's inherently low and variable oral bioavailability, though none are commercially standardized.
- **Timing**: Preclinical oral dosing studies typically administer baicalin once or twice daily with food; no human pharmacokinetic data firmly establishes optimal timing for supplemental use.
- **Standardization Note**: Consumers should verify that extracts specify baicalin content by percentage, as whole Scutellaria root products contain variable ratios of baicalin, wogonoside, and other flavonoids.

Synergy & Pairings

Baicalin is frequently combined with its aglycone baicalein and with wogonin (another Scutellaria flavonoid) in standardized root extracts; these compounds exhibit complementary NF-κB and NLRP3 inhibition that may produce additive anti-inflammatory effects greater than any single compound alone. In traditional TCM formulations such as Huang Qin Tang, baicalin is paired with Paeonia lactiflora (white peony root, containing paeoniflorin), Glycyrrhiza species (licorice, containing glycyrrhizin), and Ziziphus jujuba, with glycyrrhizin in particular reported to enhance gastrointestinal absorption and hepatoprotective signaling. Preliminary research also suggests that combining baicalin with quercetin or resveratrol may amplify NRF2/HO-1 pathway activation and mitochondrial protection, though these combinations have not been formally tested in human trials.

Safety & Interactions

In preclinical models, baicalin at pharmacologically active doses has not produced overt organ toxicity, and in vitro cytotoxicity studies generally show selectivity for malignant over normal cell lines at relevant concentrations; however, the absence of systematic human safety trials means the full adverse effect profile in humans is not established. Potential pharmacokinetic drug interactions exist because baicalin and baicalein have been shown in vitro to inhibit cytochrome P450 enzymes including CYP1A2, CYP2C9, and CYP3A4, which could theoretically alter plasma levels of co-administered drugs metabolized by these enzymes, including warfarin, statins, and certain antivirals. Contraindications have not been formally defined for human use; caution is advised in pregnancy and lactation given the absence of safety data, and traditional TCM contraindications include use in cold-deficiency patterns or concurrent spleen-stomach deficiency. Individuals taking immunosuppressants, anticoagulants, or hepatotoxic medications should consult a qualified clinician before using baicalin-containing supplements, as interaction risks remain incompletely characterized.